Completed
Frequency of Symptoms of Ovarian Cancer in Women Presenting to Primary Care Clinics
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
PARP Inhibitors in Ovarian Cancer Treatment - Webinar - Ambry Genetics
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 Disclosures
- 3 OUTLINE
- 4 GOALS LEARNING OBJECTIVES
- 5 Cancer Probability for Females at Birth - USA
- 6 Frequency of Symptoms of Ovarian Cancer in Women Presenting to Primary Care Clinics
- 7 EPITHELIAL OVARIAN CANCER SIGNS
- 8 OVARIAN CANCER CLASSIFICATION
- 9 Epithelial Ovarian Cancer Cont... Five main histologic subtypes
- 10 Regulatory Pathways
- 11 Mucinous Carcinoma
- 12 Standard of Care
- 13 Chemotherapy Recurrent Disease Platinum Sensitive
- 14 Conventional Chemotherapy Side Effects
- 15 Cost Comparison Among Ovarian Cancer Treatments
- 16 Hereditary Susceptibility to
- 17 Clinical manifestation of hereditary ovarian cancer
- 18 LIFETIME RISK ESTIMATED IN BRCA1 & BRCA2 CARRIERS
- 19 BRCA1-RELATED OVARIAN CANCER
- 20 Hereditary breast and ovarian cancer syndrome (HBOC)
- 21 Targeted Therapies
- 22 Poly(ADP-Ribose) Polymerase (PARP) inhibition in ovarian cancer
- 23 PARP Inhibitors: Mechanism of Action
- 24 PARP Family
- 25 PARP Inhibitors Background
- 26 High Grade Serous Cancers (HGSC) & BRCA mutations
- 27 Phase I trial: Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
- 28 Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer
- 29 PARP Inhibitors: Properties & Side Effects
- 30 Olaparib Clinical Trials
- 31 Ovarian cancer trials PARP 1 & 2 Inhibitors
- 32 Targeting Angiogenesis: VEGF
- 33 VEGF: Tyrosine kinase Inhibitor
- 34 Randomized phase II trial: Olaparib with Cediranib vs Olaparib alone in recurrent platinum sensitive
- 35 PARP Inhibitor Side effect Profile
- 36 In Summary
- 37 Targeting Therapies: Summary
